October 3, 2018 — Leica Biosystems announced the U.S. launch of MammoPort, the first integrated specimen containment and transport system forbreast tissue biopsies.
"Mammoport is the only tissue containment system which unites pathology and radiology colleagues in their common desire for maintaining tissue integrity throughout the entire radiological tissue acquisition to the pathologicdiagnostic process," said Darius R. Gilvydis, M.D.,2022世界杯篮球预选赛赛程specialist at Edward-Elmhurst Health.
With medical errors representing a leading cause of death, experts recommend developing consensus protocols that streamline the delivery of medicine and reduce variability to improve quality and lower costs in healthcare. By integrating MammoPort with the Mammotome revolve breast biopsy device, the tissue containment and transport system is standardized, minimizing the potential for error and tissue damage.
Current breast biopsy methods require over 300 different processing steps and 14 interdepartmental handoffs, resulting in an increased chance for tissue damage, according to Heather Renko-Breed, global product manager at Leica Biosystems. MammoPort eliminates the need for manual tissue handling by radiology technologists, protecting the quality of the biopsied tissue and enhancing ease of use.
"Mammoport is the first system to completely eliminate unnecessary tissue manipulation and calcification separation, therefore maintaining critically important tissue orientation, size and integrity," said Gilvydis. "This is performed without crush damage to the tissue from tweezers as with other systems. This maintenance of tissue integrity allows improved diagnostic accuracy, which can lead to improved patient treatment and outcomes."
旋转乳腺活检设备自动将组织放入组织托盘。然后，放射技术专家将装有样本的托盘插入Mammoport容器中，然后将其运送到x光机。一旦钙化被确认，放射科技术人员在容器上标记出感兴趣的乳房核心，将其放入福尔马林中，无缝运输到病理实验室进行检查和处理。
MammoPort eliminates the need to manually separate tissue with calcifications from non-calcifications, helping prevent potential medical errors. The specimens remain individually contained to maintain the orientation and location of the calcifications, and the marked container helps to ensure the proper patient information and critical specimen identification of calcifications remain intact throughout the process.
"The hard work of detecting thebreast abnormality, acquiring the tissue during thebiopsyprocess, can all be undone by manual crush manipulation during the separation of tissue and calcifications," said Gilvydis. "Mammoport eliminates this pitfall and helps bridge tissue integrity throughout the acquisition and diagnostic process from radiology to pathology."
For more information:www.leicabiosystems.com
August 16, 2022
